American Journal of Biomedicine and Pharmacy
https://biojournals.us/index.php/AJBP
ISSN: 2997-7177

Advancements in Computational Chemistry for Personalized Medicine and Drug Discovery

Ayaat Talib Abd Mutlak, Israa Sabry Altaif Youssef, Athraa Alaa Gorthe Fande, Khwala Naazim Hussain Ali
University of Anbar College of Applied Sciences-Heet Department of Applied Chemistry

Received: 2024, 15, Jan
Accepted: 2025, 21, Feb
Published: 2025, 31, Mar

Annotation: Computational chemistry has become an essential component in the advancement of personalized medicine and drug discovery, enabling the prediction of drug-target interactions, optimization of drug candidates, and acceleration of therapeutic development. However, the field still faces a knowledge gap in fully integrating molecular modeling, artificial intelligence, and multi-omics data for accurate and individualized treatment design. This review systematically explores computational methods such as molecular docking, QSAR, molecular dynamics simulations, and machine learning approaches applied in drug discovery. By analyzing case studies on cancer and cardiovascular diseases, the study reveals that computational tools significantly enhance the precision of drug design, reduce development costs, and improve the effectiveness of tailored therapies. Results demonstrate that integrating data-driven models and computational chemistry optimizes both target identification and compound screening, directly contributing to more effective and safer personalized treatments. The findings underscore the importance of interdisciplinary collaboration, real-time data analysis, and regulatory adaptation to fully exploit the potential of computational chemistry in modern healthcare.

Keywords: computational chemistry, drug discovery, personalized medicine, molecular docking, machine learning, QSAR,

molecular dynamics, precision medicine, data-driven models.

1. Introduction to Computational Chemistry

The pharmaceutical and biotechnology industries are investing very heavily in computational chemistry services and software right now. The FDA states that over 50% of drugs are discovered through computational chemistry services. The top 5 pharmaceutical companies are forecast to more than double their spending on computational chemistry services. In general, the resource-constrained industry is increasing the proportion it spends on computational chemistry services because of the potential cost savings involved in being able to drop the number of compounds you have to test experimentally as early as possible. The computational chemistry can be used pretty well at all stages of drug discovery, from target identification all the way through to the marketing application phase of drug development. Broadly speaking, modeling services should fall into 1 of 2 categories; services that cover standard, well established techniques like mining of historical data, QSAR modeling, docking of ligands with protein targets, micron simulation, and the like; services that cover relatively new and emerging technologies. Broadly speaking, the more experienced a modeling team is with a new technology, the more useful their results will be. However, the timelines applying to acquisition of expertise can be very long, sometimes prohibitive. Research and development teams are concerned with the Affordable Care Act.

R&D leaders are having difficulty interpreting the potential impact of the Supreme Court decisions, and the new paradigm in the healthcare environment in general. The industry is going through massive and exciting changes, but these can also be scary and bewildering times. As a scientist in a small- to medium-sized company, a director of a research institute, or a manager in a large research establishment, you are highly-trained professionals who serve to instill confidence in the direction your company is taking. You owe it to your teams to demonstrate you have what it takes to understand and deal with the seismic changes in our industry. You must develop strategies that allow you to take advantage of the changes affecting the industry. In as with any rapidly changing environment, strategic planning and high-quality, well researched information are crucial. [1][2][3]

2. Importance of Personalized Medicine

In the past 30 years, the rapid development of computer hardware and algorithms has enabled researchers to implement and create a variety of computational models, providing a powerful tool to understand and predict drug activity as well as the interaction among drugs, proteins, and genes. In the last decade, computational chemistry, as a very active cross-disciplinary research area, has achieved great progress and success in both basic and application research. This review discusses the principles of major models on the basis of their scientific insight and the general ideas of the algorithm itself. The importance of predicting drug activity and distinguishing between inactive and active compounds has made computational pharmacochemistry an emerging area with broad applications in drug design, virtual screening, and the rational design of drug metabolism. As academia, industry, and governmental agencies pay more attention to the environmental and health problems that can result from drug metabolism, understanding and predicting the metabolic pathways has become significant in drug discovery and risk assessment. In recent years, a lot of work has been done and certain progress was achieved in predicting the sites of metabolism and the metabolic pathways using computational models. Earlier works on the modeling of transport activity compared to the prediction of drug activity and metabolism have maintained a much slower pace since predicting the different types of absorption, distribution, metabolism, and excretion properties of a drug is more complex and remains less understood. Another direction for further research is the modeling of the activity and metabolic

interaction between drugs and proteins such as enzymes and membrane receptors. Products that can predict a drug's effect on critical enzymes and receptors could assist researchers in the process of drug discovery and provide new solutions to serious drug safety problems. [4][5][6]

3. Overview of Drug Discovery Process

The drug discovery process is long, complex, and costly. The target identification is the initiation. It executed by exploring numerous feasible therapeutic routes from numerous accessible biologic and therapeutic data, for example, from high-throughput testing, gene-expression assembling, protein medicine, and scientific trial details. Observations of track records are pivotal in enabling researchers to determine medicinal expressions and to seek hypotheses. Throughout the fabrication drug discovery process, computational biology and chemically relevant technologies fulfill a number of relevant and useful goals. Endeavors to appreciate a medicine are frequently opted for targets and numerous chemicals, limiting investment resources across the sorted collection of alternative targets and possible medications. Pentathlon and deconfliction, for instance, may be accomplished through computational technologies. Variability is also predicted virtually, such as drug fungibility, cell development level affection, etc. Descriptors of forecasts, behavioral patterns, therapeutic indexing, chemical annotation of medicines, etc. (compound-based) In the course of the initial cure discovery process, the compound performance against the goal is mainly examined by testing the conventional physical chemical compounds. However, an exponential increase in the number of combinatorial compounds and shifted towards the phys-resistance more than the lipophilic was demonstrated in accordance with the emerging trends in high much compounds/library. QSAR technology, simulated pharmacokinetic technology, transdermal barrier//permeability technologies, bond/materialomics technology, etc. Starting material of Medicine also plays a vital role for the manufacture of desired dose product in terms of quantity and quality. The efficacy of misleadingness and the cost-effictiveness of Medicine will significantly affect the marketability of medicines. After the completion of synthetic intermediate trials and the inventiveness of the brightest, research to optimize Manufacturing Method of Medicine can improve the value of Medicine. Relevant research can also mend/suggest a new aim or synthetic medium. Therefore, the determination intuition of the researchers is strengthened. [7].

4. Computational Methods in Drug Design

Computational methods are now consistently used even in academic research projects for drug design. This is propitious for researchers as medicinal chemistry is a complex discipline, in which a great many matters must be understood. De novo drug design or virtual screening can reveal hidden knowledge in existing data. This collective model can easily become too complex. The researcher tends to average these interacting properties over some or all system of interest to render them compatible with software libraries that accept data as various simple function or descriptive forms. Unfortunately, biological systems, even when simplified to model aspects of interest, still involve complex interactions. While, in-silico techniques for drug discovery are increasing in both number and in respect the novel areas in which they are being applied, they are still some way from realizing the potential to mechanistically models important biological processes directly and modeling relevant and specific parameters, capable of being measured experimentally, with enough accuracy to aid in the design and synthesis of either the drug itself or the experimental methods employed to evaluate its effectiveness. Rather than seeking to inform drug design [7] suggests that computation may maximize some one quantifiable activity, for example, by seeking those molecules in a database most likely to bind to a given target. Smaller and more focussed models, underpinned by sound logic and tested with respect to specific well defined problems offer the best hope for computational chemistry, in partnership with empirical and experimental approaches, to facilitate the design and discovery of new drugs.

4.1. Molecular Docking

The estimated affinity of a ligand for a target protein is the paramount measure in numerous

research projects. Despite its fundamental importance, economic restraints usually denounce costly issues such as labor-intense high-throughput screening assays as well as needs of slow and technical methods to exogenously market the number of possible drugs. However, biology, protein binding kinetics and thermodynamics are accountable for the absence of rapid comprehensive methods for the establishment of free energy of binding of a ligand to a protein target.

Reasonably since decades, scientific community relies singly on computational methods to enhance the prediction of these quantities [8]. Anyway, results are by far suboptimal because the scoring functions meant to calculate the energy of interaction between ligands and proteins do often miss critical terms and those terms are calculated in the context of an extensive simplification of reality. For that reason the prediction of the free energy of binding of a ligand to a target protein is encumbered by an intolerable degree of uncertainty.

4.2. Quantitative Structure-Activity Relationship (QSAR)

Hopes and reality for personalized medicine have emerged since the implementation of the human genome project. However, despite all the advancements, patients are still suffering the adverse effects of drugs day by day. Although drugs are continually screened for side effects, problems often occur only after long-term, in vivo, and unforeseeable interactions of drugs. Nowadays, computational chemistry studies give an outrageous amount of insight into the human body's biological interactions. For these reasons, computational analysis is implemented before the clinical phase of the drug-discovery processes. Since the interactions of known molecules with the biological receptors have been solved, discovering a small new molecule – perhaps a possible drug – is left to computational methodologies that require a chemically simple definition of the receptor. Earlier studies inspired by quantum chemical interactions between small molecules and proteins have hope for strong success. However, since proteins are flexible objects and able to occupy multiple conformations in the interaction phase, possible success is still not close. The next methodologies are simplified to study these geometrical difficulties, and a geometrically simpler and more rigid pinpoint of the small molecule-protein interaction is done. More than a handful of methodologies are reported in these sence, and today the biological interaction investigation is performed on the pharmacophore docked sites of the molecules [9].

4.3. Molecular Dynamics Simulations

Molecular dynamics simulations (MD) and computational chemistry have assumed a growing role in the pursuit of new drugs and the tailoring of personalized therapeutics. In combination with disease models constructed using systems biology, computational simulations can elucidate shape and shape-induced docking of small-molecule compounds, elucidate pathways to disease onset, support targets for interrupting these pathways, propose design strategies for agents that modulate specific molecular events in these pathways, construct and parameterize molecular models sufficiently accurate for reconstructions of identified compounds, even ab initio, and generate migration profiles for designed all-molecular and combined pharmacological and genetic targeting of cells involved in patho-physiological processes [10].

Molecular dynamics (MD) simulations have advanced substantially over the past two decades. MD simulations are poised to become powerful tools for investigating the dynamic interactions between potential small-molecule drugs and their target proteins. The molecular structures of disease-implicated targets influences the identification and optimization of small-molecule ligands. Structure-based computer-aided drug design (CADD) further augments rational design by using computational methods to reduce the physical experiments required for hit identification. Traditional CADD techniques focus on static protein structures contrary to MD simulations that have the dynamical evolution of the system. Different ligands often stabilize distinct yet equally valid pocket conformations. With the emergence of cheap, powerful computers, as well as better force fields and Markov models, MD simulations are becoming widely used. CADD researchers routinely use MD simulations to unravel pharmacologically

relevant conformational changes and binding-pocket dynamics [11]. Broad coverage of the conformational landscape of the protein poses significant challenges and has created a demand for novel methodologies that generate multiple pocket conformations, such as ensemble docking. To identify structurally diverse small-molecule ligands that bind to a dynamic binding pocket, CADD methodologies must account for multiple physiologically relevant pocket conformations.

5. Role of Machine Learning in Drug Discovery

Drug discovery is a very complex and costly process. It has been estimated that it would take more than 2 billion dollars and approximately 10 years to shrink the time for finding an optimal drug candidate. Early stage drug discovery is a step-wise process where hit molecules are required to meet certain defined criteria in order to ensure their efficacy and quality before proceeding to the next stage. This results in a number of selected molecular properties that need to be optimized [12]. Computations, in particular, machine learning (ML) models, can predict the values of screened compounds without the necessity of conducting costly laboratory experiments. In this work, various ML models such as Random Forest, Extra Trees, AdaBoost and Gradient Boosting, used to predict a number of molecular properties such as aqueous solubility, cell permeability, propensity to bind key drug bio-transformations, such as cytochrome P450 and microsomal stability, were presented.

ML is typically applied to fit a model to a known data set to make predictions from new inputs. Concurrently, there is an increasing need to be able to make decisions based on very large amounts of data in a timely manner. For the prediction of molecular properties, it is therefore crucial that the algorithms used are both fast and accurate. ML models such as Random Forest, Extra Trees, AdaBoost and Gradient Boosting allow the fitting of model to both linear and non-linear relationships using a great flexibility in model specification, thus increasing the predictivity of the models.

Docking algorithms, molecular dynamics algorithms, quantum mechanical/molecular mechanical (QM/MM) simulations and empirical scoring functions were discussed, focusing on small molecular properties in drug discovery. Docking algorithms provide a way to predict binding poses of ligands to their target. This is done by using information on how the two molecules interact with each other, and thus predicting a score for the ligand-target interaction. More sophisticated estimates on binding affinity can be obtained using molecular dynamics algorithms or QM/MM simulations. These simulate the movement of both atoms and molecules by large computational means to approximate the force field that drives this movement being useful for example in in silico mutagenesis applications. A simpler and faster approach is the use of empirical scoring functions such as Free Energy Perturbation or SIE models. These provide a way to estimate the dependency of a ligand-target interaction score from geometric and energy terms of the interaction. [13][14]

5.1. Data-Driven Approaches

Advances in computational chemistry and data-driven machine learning in particular provide pivotal tools to leverage the benefits of personalized medicine, drug repurposing, and the discovery of innovative drug molecules and patient therapy designs. Data can be mined and mining results, for example patterns, significant rules and highly predictive models, can be exploited for technology-driven chemical reactions, product designs, drug target selections, and therapy optimizations. Recently, the term Pharmainformatics was introduced for that technology field of industry and academic research. In this overview, I outline and put into perspective the computational chemistry approach applying these methods to date. These spectrum of modern data-driven machine learning making will be exemplified by recent investigations. Approaches being presented cover the mining and modeling of receptor activities and selectivities, structure-activity and structure-selectivity relationships by alignment-free and alignment-based physico-chemical and topological methods, similarity considerations on the mechanism of molecular actions or the toxicity of drug molecules by means of post-genomic data, molecular fingerprints,

and nucleotide or protein sequence information. Generally, these concepts allow a wide spectrum of molecular data and analyses to be approached which will revolutionize future challenges from this sector of industry and pharmaceutical research in the chemical, biological, and medical disciplines [7]. With recent advancements in computation, there is an increasing number of data analysis tools and models becoming available for researchers, which form a critical building block for the implementation of in silico strategies in a wide range of scenarios, including personalized medicine and repurposing new applications and drugs. On the other hand, modern computational methods are able to handle a variety of biological, medical, and chemical data types and sources, hence facilitating the simulation of complex problems in the manufacturing of pharmaceuticals [15]. Similarly, optimization is more goal-oriented and requires fast evaluation and customization of a large design space based on predictable and desirable design outcomes. Aspects of these mutually differing perspectives will be of contemporary interest and the focus of this review.

5.2. Predictive Modeling

This methodology evaluates machine learning classification models using a 5x3-fold cross-validation against a publicly available version of Chembl_20. The models encapsulate 2048 bit extended-connectivity fingerprints and, after a prospective validation exercise, can be obtained within the KNIME analysis platform. By running pre-implemented components, users can generate and evaluate models in new target prediction exercises. This methodology supports large-scale in silico repositioning of already approved drugs for rare and neglected diseases [16].

The two new components have been added to a prior report that found predictive Bayesian models for 900 binary classification tasks. The results extend that work by mining Chembl_20 for over 9000 assays, viewing AUC-ROC as well as B, and incorporating 789 tasks with on-target false positives excluded. This report has benefited from using the Bayesian models built in KNIME and has therefore decided to contribute them back to the community. These pre-implemented KNIME components (a descriptor calculation sub-workflow and filtered Naïve Bayes predictor) make it a simple matter to apply the same methodology to new targets. Ultimately, the best QSAR classification models for about 3500 targets were evaluated utilizing 2048 bit global extended-connectivity fingerprint descriptors.

6. Case Studies in Personalized Medicine

Since the announcement of the Precision Medicine Initiative in 2015, precision medicine has developed rapidly in various aspects of healthcare. It is anticipated that the next decade will see the completion of the human personalized medical map. Computational technologies, playing an indispensable role in precision medicine, are expected to generate and analyze multiomic and phenotypic data of individual people including gene, RNA, protein, metabolite, disease, health status, and environmental factors from large populations, to promote the growth of healthcare strategies at the individual level. Increase in the availability of computational models or software systems has been achieving different applications in bioinformatics and systems biology. Computational models provide a structural framework for obtaining information not available by other approaches, either due to the limitations of the experimental techniques or the involved theoretical models. There are many health measurements taken during routine hospital visits, including imaging, blood, and urine tests. As a result, healthcare systems in many countries are increasingly generating personalized multi-omics and medical image data for each clinically diagnosed patient, which is expected to improve patient care by creating a model of patient health. This has spurred numerous research collaborations by collecting data across research consortia to promote a new generation of computational models that analyze these rich data. Computational models have helped in discovery, diagnosis, and therapy in numerous cases, providing the rationale for exploring training options and making predictions [17]. However, a number of challenges remain that are necessary to fully realize the promise of personal data in clinical applications.

6.1. Cancer Treatment

In the submission, the article focuses on the impact and importance of computational chemistry, AI, and machine learning in general to provide a fast, cost-effective, and personalized approach for the development of new therapies. Great attention is focused on cancer treatment, which remains a substantial challenge for contemporary science and society. The proposed computational method and the imperative aspects of its flexibility and personalization may not only provide significant improvements to cancer treatment discovery, particularly, but also to other pressing questions related to health care, ergo enabling progress in fundamental understanding and medicinal treatment of a biological entity, and accelerating the development of faster high-throughput models in pharmaceuticals. Cancer is emanated as a wholly epidemiological aspect of civilization's present state. By estimation, there is incidence of cancer in one out of three people over one's lifespan. There is increased investment in longevity, the personal desire to live at a deep individual level, positive perception of well-being, and desire to reduce the susceptibility of mortal illness. It is noted that scientific prophylaxis is currently mostly driven by biological science and biotechnology. It is further emphasized that cancer is an avoidable disease and largely preventable due to the typically prolonged latency of this germinating disease. Longer life expectancy increases the likelihood of developing cancer over a lifetime, and with longer average expected and average individual life spans comes associated fears. Efficient condensing of preventive approaches and emphasizing the importance of a plethora of factors, such as dietary habits, standards of living, genodietetics, gene–environment interactions, dulled-sensing obesity, and stress, is noted. Additionally, an intensive computer modeling investigation has been performed. On this note, focus has been shifted to consider the most malignant of endemic tumors (mesothelioma) and to develop modeling and semi-empirical estimation for HR-model endpoints. Due to nonlinearity inherent in the modeling inputs, FNMLA techniques have been envisaged, combined with high-throughput molecular event space point prediction, failing to fall within the requirements of the classical tiered-testing and emphasis on adhesion and predictions doubt. [18][19][20]

6.2. Cardiovascular Diseases

Cardiovascular diseases are the principal cause of death worldwide. As such, these diseases impose economic burdens on developed and developing countries. About 30% of global deaths are due to cardiovascular diseases [21]. The amount of cardiovascular-related data to be managed has steadily increased with the benefit of digital technology. Concerning digital biomarkers, conventional data sources include vital signs, diagnostic imaging, and laboratory test results of blood or urine. Currently, tele-ECG, tele-phonocardiography, and tele-rhythmo (auscultatory) graphy are used to diagnose cardiovascular disease in daily life. The above digital health assessments aim to forecast disease states. Such predictions will come from a variety of approaches, including patient-specific models and data-driven machine learning. A Computational Patient will be introduced that includes, refined, and extends landmark cardiovascular, renin-angiotensin system (RAS), and diabetes models. Methodology outlines the heterogenous and multiscale Computational Patient model that studies dynamical circulatory conditions and systemic biomakers. It will be shown how this is used for experiments designed to better understand and forecast the dynamic properties of vaccine and disease states at both individual and demographic levels. With the contemporary well-being and illness scenario as a base, basis simulations and data analysis have been performed in a variety of distinctly stressed and/or treated environments. Want is to outline results future must care about the different method choices made and the significant new observations obtained. A systemic approach is to develop, link, and use novel mathematical methods and mechanistic models of cardiovascular, RAS, and diabetes as a Computational Patient. Experiments have been performed to demonstrate the utility of the Computational Patient. Findings indicate the strong influence of transient dynamical responses on acute state circumstances. [22][23][24]

7. Challenges in Computational Chemistry

Computer-aided drug discovery has been an important subdiscipline of computational chemistry for <number> years and different types of computational methodologies have been developed and applied in drug discovery environments, often with varying degrees of success [7]. In general, public perception of computational methods strongly connects with respect to how they are employed across different fields of science. This statement is valid for both small molecule and macromolecule research. For instance, in the context of small molecules, chemoinformatic and structure–activity relationship methodologies have been rather broadly accepted and established tools in drug discovery environments. Structural bioinformatics, on the other hand, has come under constant and widespread criticism for lack of accuracy and developing predictive models of little value to the end user. Progress in this arena has been slow and rather mixed.

In drug discovery environments, efforts are often made to tackle extremely complex questions, i.e. with high industrial or medicinal chemistry expectations, using methods that are actually incapable of addressing such issues. In general, greater emphasis should be placed on the development of computational approaches for the analysis of experimental data generated by non-computational, methodically very diverse experimental techniques. [25][26][5][27]

7.1. Data Quality and Availability

The benefits of Personalized Medicine in drug discovery have been widely discussed and plenty of literature has been devoted to its general aspects. This dissertation focuses on a narrower perspective consisting of the integration of Genomic Studies to prioritize drug targets and the subsequent development of new active compounds. According to available genetic databases, nowadays the cost of genotyping has been dramatically reduced so that large amounts of genetic data are currently available in electronic format. At proof of concept, the author used them to prioritize some known targets for the study of neurodegenerative diseases and came up with a noteworthy list of future candidate genes. A chemical strategy to therapeutically modulate protein–protein interactions (PPIs) that may be applied to potential new molecular targets is then proposed. Regarding compounds, whereas genomic studies have the ability to produce/store replicable data, similar features are not always true for chemical studies whose results are often manifold and incomplete. Indeed, hundreds of bioassay repositories exist, but there are concerns on the reliability of the corresponding datasets. Unfortunately, the cheminformatics community foresees that, in chemical terms, the 'tipping point' of acceptability is unreachable due to the preponderance of so many active data readily available. To examine the potential effects on models arising from the use of uncurated data, a retrospective analysis of models predicts the sensitivity and specificity of curated models built on non-curated data [28]. Existing challenges and new opportunities are outlined to better integrate computational chemists into the fields of personalized medicine and drug discovery. Exemplary case studies are reported, which show how cheminformatic tools can significantly impact the yield of projects. Besides traditional applications, recent innovative works on polypharmacology, the reinvestigation of approved old drugs with newly developed methods, and the investigation of new targets with public gene expression data are illustrated.

7.2. Computational Resource Limitations

The application of computational chemistry to personalized cancer medicine and the discovery of new drugs for cancer and other diseases is continuously increasing. Large academic research networks, public-private partnerships, and pharmaceutical companies focus in the field have been founded internationally, and the volume of associated scientific literature is correspondingly vast. Advance molecular modeling and bioinformatic technologies in the context of personalized medicine, industry and the discovery of new drugs.

Regarding personalized medicine, the sequencing of tumor genomes for the creation of patient-specific drug combinations and mining of datasets with experimental and bioinformatic methods

for the identification of highly efficient inhibitors in protein-metabolite-protein networks are discussed. For industry and drug discovery, the compound searching by pharmacophore algorithms and the prediction of the activity in the target of potential drugs by molecular dynamics and docking simulation are described.

Questions to computational chemists and bioinformaticians include the following: Are there software and hardware resource prerequisites for entering this field of research? With a limited budget for software licensing, are there free accessible programs that are sufficient? Will after the installation of large biosoftware packages access to pricey databases also be necessary? How essential is strong mathematical and algorithmic background? How much time will be spent on data scrapping, reformatting and recalculation of downloaded numbers, filtering of giant databases, and generation of unified datasets? How can one obtain computational time on high-performance computing clusters without direct personal experience? What is a reasonable balance between "developed creatively in-house" solutions and "readily available commercial" programs? In approximately how many publications per year should results be published from the obtained data in order to remain competitive with other interdisciplinary or cheminformatic consortia? How long is the quality control and revision process for the first submission of such publications?

8. Future Directions in Computational Chemistry

There is general agreement that the role of computational chemistry in drug discovery has advanced by leaps and bounds since quite recently . Improvements in computational methodologies, including quantum methods and molecular mechanics, have placed calculations on a more rigorous footing. At the same time, the exponential increases in computer power have addressed time and size constraints that once limited such studies to the simplest of systems. As a result, a broad range of molecular systems is now within reach of theoretical calculation. In drug design, computational chemistry has been among the successes. Some of the triumph comes in the form of applications of the theoretical chemistry of drug design, such as those molecular modeling studies that seek to understand the mimicry that lies at the foundation of the interactions between ligand and receptor. Nonetheless, the value of these studies remains limited by the nature of the force fields that describe these interactions, and these are heuristically based at best.

There is great optimism that the field of drug and protein design via computational chemistry will be transformed in the years ahead by an increased understanding at the molecular level of biology. When an amino acid is mutated in a specific enzyme known to be the target of a class of drugs, the binding of the drugs may become less effective. The goal is to use this information to design new drugs for that target, on the basis of models of this type of mutation. Indeed an increasing amount of information is being unearthed concerning the nature of the thousands of proteins in the body, what functions they perform, and how they perform these functions. It will not achieve these things from a data bank of static protein structures. Rather, all describe the molecular setting as too complex and too dynamic to be adequately sampled in a single conformation. Consequently, the theoretical basis of computational protein design has been relatively more primitive than that of either small molecule calculations or small molecule reminiscent calculations of drug design. However, is predicted much exciting new information coming out of the field of biophysics in the coming ten years, much of it due to advances in experimental techniques, such as multidimensional nuclear magnetic resonance spectroscopy. It process the field of protein and drug design will explode with new hypotheses to be tested experimentally and therefore a vast potential with implications for the treatment of disease. [29][30][31]

8.1. Integration with Genomics

Macromolecular structure plays an irreplaceable role in linking the physical and chemical origins of genetic events and drug action to the systematic response at cellular, tissue, and organism

levels. Thus, the incorporation of physiochemical-based macromolecular structure modeling with data-driven and mathematical-based pharmacodynamics, pharmacokinetics, pharmacogenomics, and systems pharmacology will enhance the power of modeling a predictive personalized drug response and shed new light on living systems [32]. Conversely, in the context of complex diseases, drug response often results from perturbations to several cellular components, either through a disease-induced disturbance or a therapeutic action. In this sense, a model of the biology of a complex disease, based on molecular structures, can be used to infer how best to restore cellular components to their normal states, that is to predict a rational drug (or combination of drugs). Structural systems pharmacology is an integrated platform that can be used to address this challenge and give molecular insight for the prediction of drug effects on complex diseases and further opens the doors to tissue-level systems pharmacology. However, one of the barriers to this vision is limited structural coverage of macromolecules and their complexes. Similarly, there is a growing need to understand drug effects at the systems level. Broad consideration is given to advances that matter for a comprehensive 3D modeling of a proteome in its applications to a systems-level prediction of the personal response to small-molecule drugs. Tissue-level systems pharmacology marks an advance to a new quantitative paradigm of pharmacology, which will lead to an improved mechanistic understanding of drug behaviors and therapeutic responses in cellular networks so as to guide drug discovery.

8.2. Real-Time Data Analysis

An impressive amount of progress has been achieved lately in cheminformatics, which is allowing the treatment of preparative, spectrometric, metabolic, and computational data in an integrated manner within a systems biology approach. In order to organize for the best, one approach is to pre-process the data into manageable file formats and then to store tables into DataBase Management Systems. SQL language can be easily used to retrieve data together with a number of MATLAB toolboxes. Currently, other solutions are more flexible and powerful, even interfaced to JAVA and HTML languages, however the basic key points remain valid.

Each single and essential products of a standard computational laboratory can be effectively loaded into SDF-MOL files and then treated by inventories of algorithms, which are integrated into TRIPOS SYBYL-X-2.0. One major and acknowledged problem of the progress in chem- and bio-informatic is the lack of homogenization and standardization in the choice of formats and terms when storing data [33].

Devices with proprietary software, such as mass spectrometers, NMRs, etc., produced raw data, which are usually immediately pre-processed and stored into vector tables. Numbers of vendor-independent software turn raw data over to understandable results only as multi-column text-files, losing typically about a decimal digit of precision in the production of each figure. In general, stored files must provide numeric item codes that allow an univocal range set, from which ranges themselves will be inferred together with suitable smoothing, tapering, thresholds, etc. This results in a sharp reduction of data's information content, which may not always be acceptable. The only way to avoid, and at least limit, this distortion is to run raw data processing software from original machines providers.

9. Ethical Considerations in Personalized Medicine

There is a rapidly growing amount of personalized data in today's medicine. The availability of these measurements holds immense promises for both diagnosis and treatment of diseases at the single-patient level. The complexity of the data poses significant challenges in its general usability due to the underlying heterogeneity of samples as well as inter-patient variability. Computational models provide a structural framework to analyze these data through their contextualization in mathematical descriptions, be it mechanistic modelling or machine-/deep-learning. However, several challenges remain to fully realize the possibilities of personalized data in clinical practice, particularly regarding data provision, model building, and legal issues and ethics.

The ethical implications of personalized medicine are manifold: access and justice, lack of attention to social determinants of health, informed consent, autonomy, manipulation, utility and predictive power, privacy and the digital shadow, and physician's role. A recent intensive ethical discourse may not be neutral in the conception of patients' interests and rights. Nonetheless, classical views of ethical considerations concerning benefits, burdens, costs, risks, harms, and rights are relevant to health care whenever the concept of personalized medicine is in place, as the development of personalized medicine and its introduction into the mainstream public and private healthcare is essentially medico-technological. Before analyzing the ethical implications of the deep phenotyping and data analysis approaches, a short overview of deeply phenotyped data is provided. In the actual discourses and policy-making contexts, deep phenotyping refers to a variety of methods to analyze genetically and molecularly the patients' constitution and disorders.

Computational methods developed to predict disease progression or stratify prevention or therapeutic strategies are discussed. Since scientific and technological research advances in a similar manner, computational precise medicine is also designed to account for the mathematical, scientific, and computational aspects. However, controversial ethical issues have been minimized so far. Pooling scientific knowledge is believed to accelerate the drug discovery process. Simulating the effects of compounds in complex disease networks becomes a crucial tool. Improved assessments of risk-benefits for each patient could promote regulatory acceptance of new drugs.

10. Regulatory Aspects of Drug Discovery

Regulatory approval for the introduction of a new drug product into the market is a complex, expensive, and time-consuming process. As such, it remains the purview of large pharmaceutical companies. Early mistakes in the selection of a series of compounds tested in patients can result in a costly clinical failure, and the burden of compound selection often leads to the outsourcing of this decision to specialized organizations. Given the success of computer-aided drug design (CADD) in predicting the activity of compounds in experiments, some importance is being attached to the likelihood of success of a candidate in development by the application of a CADD method. However, regulatory acceptance of CADD in the pipeline remains poor and decisions concerning the control of the design of the trial such as the optimal phase of development to test the compound, the patient demographics and the optimal dosing, tend to remain in-house. Regulations in most countries require that the appropriateness of the study be demonstrated with results from experiments. If it is to achieve a predictive and regulatory role, the development of CADD must be undertaken prospectively (i.e. using only knowledge of the system available at the time the experiment is designed) [34].

Prospective work in this area is minimal and the regulatory aspects of such work have never been explored in the public domain. The potential of a prospective methodology to positively affect patient outcomes is analyzed in the context of regulatory realities. It is concluded that the proportion of compounds selected for formal development that go on to be licensed is increased through the application of a CADD methodology; a result seen to be reasonably robust to the definition of 'positive'. However, the regulatory scene is found to be complex. The only pragmatic way in which CADD could be used in the design of clinical trials to take full advantage of successful predictions and avoidance of failures would be in the development of testable rules. Regulatory agencies have never received work of this nature and prefer empiricism and transparency in experiment design. Furthermore, the proprietary nature of many CADD methodologies and the exactitude of many methods to a particular instance could compromise the flexibility crucial in the design of a trial in practice.

11. Collaborative Approaches in Research

Personalized medicine—adjusting the medical treatment strategy to each patient's needs and characteristics—poses challenges for research that can be addressed effectively by computational

and structural methods. The recent biennial international CCP5 Conference took place from April 13−16, 2015, in Valetta, Malta, at the University of Malta Valletta Campus. It constituted the eleventh event in a series that began in the year 2000 with the aim of bringing together the communities of powder diffraction with computer modeling of materials at the atomic and molecular levels. The four days of the meeting brought the focus of the worldwide diffraction and modeling communities to influences of the local atomic and mesoscale structures on the properties and phenomena of a range of materials. It also included the application of a broad variety of local structures of pure and complex molecular, ionic and metallic systems. The 2015 event took place during the Malta EU presidency and thus enjoyed significant support from the local enterprise, and more than two-thirds of the financial attendees came from the island nations of Southern Europe [7].

11.1. Interdisciplinary Teams

Advancements in computational chemistry hold great promise for personalized medicine and drug discovery, but equally great barriers exist to their practical implementation. Herein the existing infrastructure for and main challenges to such implementation are presented, along with a possible solution involving the creation of regional centers that bridge these gaps.

The identification of a molecule with a bioactivity of interest for use as a pharmaceutical typically involves the laborious and expensive synthesis and testing of tens to hundreds of derivatives [7]. In traditional pharmaceutical research large libraries of compounds are created and screened against one or more targets with a high-throughput screening system. The possible targets are genes, RNA, enzymes or receptors that have been identified by genomics or other methods as key in a disease process, often building upon basic science advances in understanding disease at the cellular or physiological level. Computational methods are currently used for design of compounds for experimental testing in the high-throughput screening process or for screening the many compounds that result from this process for drug-like properties or bioactivity as potential drugs. Proper prediction of bioactivity requires optimization of 3D structure, solvation, and conformation. Recent advances in the specificity of molecular docking provide the possibility of rational drug design once a lead species has been identified. Proper prediction of drug-like properties requires careful compound design and an exhaustive survey of all possible compounds. API creation is currently an iterative process between computational and experimental methods. For any chemical series, computational methods can help to identify a compound’s adherence to Lipinski’s Rules and the most feasible synthetic route. Traditional visual aids are hardly adept at helping medicinal chemists sort the combinatorially generated zillions of compounds that result from these types of operations.

11.2. Industry-Academia Partnerships

Computational Chemistry and the Influence of the Health Technology Sector

The rise of computational chemistry has been driven by numerous factors including advances in computer power, software and methodology, allied to applicability across a wide diversification of sectors. This multiplicative expansion of demand has proffered a myriad of employment opportunities and facilitated an environment in which academia can more readily engage in industrial outreach. The health technology sector in particular has benefited greatly from the wider adoption of computational methods. Studies in the field of biomedical imaging have developed models which predict pulse wave velocity in young people to forecast their risk of developing hypertension in later life. Allergic contact dermatitis is a substantial global health issue with one in three women being affected. In silico modelling has been used to develop and test a novel fluorescent peptide for the detection of the offending metal allergen. The in silico model is also able to predict asymmetric turning and concentration profiles of proteins in microfluidic systems enabling the development of new methods for in-line process monitoring. The desire for greater computational capacity is also driving the manufacture of larger supercomputer systems. The first petaflop supercomputer for computational chemistry was

reported in 2008.

Industry-Academia Partnerships

Collaboration between academia and industry has recently been a topic of interest and discussion across various fields of science [35]. Its importance is widely recognized and even promoted by public funding agencies. However, the concept of collaboration between academia and industry is not new. This recent resurgence of academia−industry collaborations is spurred by financial pressures, as both parties reach out to each other to render their practice of research and development more time- and cost-efficient. Academia is leaning more toward “applied science” because public funding agencies can no longer justify spending taxpayers’ money for basic science endeavors alone. Just as industry industrializes, academia is becoming more “industrial” with interdisciplinary research centers, concerted efforts in technology transfer, corporate sponsored research, industry-based case study problems in classroom teaching, and even financing large-scale laboratory infrastructures in the hope of building a closer relationship with industry. Nevertheless, as government funding becomes more and more modest, both parties are further encouraged to fortify a “complementary” approach and even to fill up each other’s gap.

This often comes in the form of contributing knowledge, know-how, instruments and tools in addition to financial support. Many interests are at stake and good collaborations are usually under the auspices of a legal agreement stipulating the terms and conditions that protects the rights of both parties and rewards them according to their respective contribution. Collaborative research projects have been started to design and evaluate a next-generation chemical-shift-based polymer sensor array material using solid-state nuclear magnetic resonance and photoacoustic imaging.

12. Impact of COVID-19 on Drug Discovery

Pharmaceutical Research: Novelties in Computational Techniques

Drug design is an intricate and protracted task that demands awareness of medicine and a multidisciplinary strategy. The overall dream for this scientific research is to offer in-depth insight for scientists, scholars, clinicians, and individuals interested in biomedical disciplines to attain comprehensive comprehension on this respective field. The safety and efficacy of a drug are mandatory conditions that have to be satisfied before its commercialization. In actual fact, the pharmacokinetic (ADME) and toxicity properties of the sphears APIs are figured out prior to the drug synthesis in the experimental area due to various scientific research procedures, which are expensive as well as time-consuming. Accordingly, the in-silico methods to estimate their APDT characteristics play pivotal task in reducing the charges of the preclinical research study, produce swift as well as accurate results, and are highly recognized by the FDA. The intelligent assessment of biopharmaceutics and pharmacokinetics (iABPK) versions to foresee the ADME features of potential quality by design (QbD) Islatravir drug prospects is a tactic to increase the efficiency of this approach. QbD is an inventive approach that enables response variables and product attributes (CQAs) to be systematically linked with crucial quality variables (CQVs). Utilizing the RSM method, QbD was used to deploy iABPK models to comprehend Islatravir’s critical ADME trajectories with 19 vital CQVs [36]. In addition, HP-β-CD and sodium lauryl sulfate (SLS) were both investigated as transporters and co-transporters in the researchers’ RSM approach. This innovative study marks the debut of the RSM tactic, comprising multifaceted ABPK techniques, to understand an experimental inhibitory mechanism on a preclinical level in depth. It demonstrates its capability to explain how an excipient changes the API restrictions concerning absorption, distribution, metabolism, and excretion by connecting crucial drug attributes (KDAs). Thus, QbD is a useful way to improve the efficiency and relevance of the iABPK approach of the researchers for the development of oral anti-HIV long-acting drug collection [37].

This has further been demonstrated by a collection of comprehensive case studies, where

mathematical models have been utilized in close collaboration between modelers and experimentalists in order to significantly enhance our understanding of important scientific problems, as well as to elucidate methodologies that can be deployed to address similar questions across the broader scientific community. Long-term development should ultimately culminate in automation, making such studies routine and broadly deployable within the applications domain. Major challenges for both the modeling community are discussed. Best practices are those strategies that have yielded success in the past that should be reported in the scientific literature and adopted by the community at large. Inaccurate data preparation and comparison can lead to unrealistic expectations and set poor benchmarks for the future scientific research. Further, free and open tool repositories for the requirements of each modeler's work should be provided, including those for curation of raw data to permit connection between new models and historically collected measurements. Back-and-forth experimentation, as referred in the literature, should be published alongside any model-based findings found from computational experimentation, empowering and encouraging others to pursue the same comparative studies. Major development platforms, gateways, and data aggregation/information systems that operate across a large number of research labs include standard operating procedures (SOPs), making data and experimental protocols available to all researchers in an easily accessible location, leading to an increase in uniformity in the literature. In particular, for computational studies, exact surface-immersed control descriptors should not differ without justification and rationalization. Automatically when sharing the results with the wider community, it must be shared with enough detail so that the work can be reproduced.

13. Technological Innovations in Computational Tools

Recent technological innovations have directly contributed to dramatic increases in computational tools for the analysis of biological systems. While the selection of computational tools is fixed by these changes, the strategy emerges to apply a diverse set of computational resources and approaches to the attempted solution of different problems in order for an optimal choice of computational tools to be made and to use computational results as constraints for experimental follow-up work. In traditional personal treatment, individuals are treated with a generic drug or procedure in the hope of positive effects. Modern medicine is increasingly moving toward personalized treatment. Using an understanding of a patient's profile, individuals could receive a treatment regimen specifically designed for them. There is no set recipe for computational tools that can be prescribed to solve specific problems arising in the context of particular biological studies, regardless of how thoroughly these problems are defined [7]. This is because recent technological innovations have directly contributed to dramatic increases in available computational tools for the analysis of biological systems. Computational drug discovery approaches have been widely developed and are successfully applied to various problems in the field of drug discovery. Virtual compound screening and flexible ligand docking are within the most actively developed subfields of the computational drug discovery, and their development and impact are viewed.

The pharmaceutical industry has a growing demand for well-trained scientists who are skilled in medicinal and computational chemistry. Medicinal chemists and computational chemists have traditionally sought to acquire skills far removed from one another, developing a discontinuity that persists to the detriment of the pharmaceutical industry. Young medicinal chemists and related disciplines should be encouraged to understand and apply computational chemistry to their drug design projects. Several specially designed tools are presented that are suited for both novices and expert users. These tools are intended for the investigation of protein-ligand complexes at a level of detail that cannot be provided by textbook or tutorial publications [38]. Additionally, these tools can routinely be employed to handle drug discovery tasks. The tools assist in the identification of high-potential compounds, provide information on molecular determinants that contribute to the affinity of ligands toward their target protein, and offer insights into the dynamics of protein-ligand interaction. Going beyond the simple visual

inspection of ligand positioning, these tools perform sophisticated computational analyses that are deemed as essential for productive interaction between medicinal and computational chemists. In the practice of aromatic compound design and modification synthesis, biological screening plays a crucial role for the chemist to make decisions on the further optimization strategy.

13.1. Cloud Computing

The advance of cloud computing overcomes the execution limitations encountered by computationally intensive tasks and pervasive broadband Internet and wireless network connections. There also exists significant growth in the fields of cheminformatics and bioinformatics, and advanced computational tools are now becoming routinely used to make it feasible to analyze the vast amount of experimental data coming from instruments such as genome sequencers, structural biology facilities, and high throughput screening setups. Compound-related information has now been stored in a more central location within pharmaceutical organizations, and this information is secured according to the company policy guideline. The compounds are moved around the storage facilities to perform experimental procedure, and this procedure is called bioassay. The data obtained from bioassay are recorded in the user defined data fields, and it is essential to build the layout of the data first. Anecdotes indicate that a significant percentage of a scientist's work may go unreported in the literature. The bioassay procedure in the storage facility may require the compound samples to be moved and tested with biological samples. The bioassay data generated needs to be stored.

13.2. Artificial Intelligence

Advancements in computational chemistry and biology have revolutionized the process of new drug discovery. Along with the experimental procedures, computational and database research provides valuable insights for selecting appropriate targets of hypothetical drug molecules. It enhances the screening procedures to confirm drug candidates' validity against specific targets. Early phase computational procedures such as pharmacophore mapping and molecular docking procedures combine the potential drugs (or drug-like compounds) known as ligands with their biological targets (receptors or enzymes) to form the complex, ligand-target or drug-receptor complex (or conjugate) for normal repression of targets by ligands. Advanced studies such as molecular dynamics studies, atomistic studies, and ab initio calculations are used to understand the drug-receptor system behavior more profoundly [39]. The last couple of years have seen a gigantic advancement in artificial intelligence, from machine learning (ML) to deep learning (DL) and up to cognitive computing in many entrepreneurial domains. It is supposed that AI could be applied innovatively in the quadrant where pharmaceutical science and technology cross-mate. With the 'Go' approach of AI like Alpha-zero, a rapid growth is seen in application of AI to drug design and discovery. A brief introduction to AI is presented first for non-AI experts. A picture to AI from ML, DL, reinforcement learning (RL), and so on as well is provided. A construct development processes and application paradigms of ML-based smart formulation, DL-compliant disease diagnosis, and DL-oriented target identification are depicted, respectively. An enlightening table is given toward the end that lists up great endeavors and smart aspirations seen with respect to AI abruptly involved with drug design and discovery in worldwide pharmaceutical and biotechnological industries [15].

14. Validation of Computational Models

Computational chemistry has proven to be an invaluable tool in the rational design and prediction of bioactive compounds. The use of computational models are particularly useful in cases where experimental methods are difficult, impossible, or cost prohibitive. With the advent of powerful computers, less empirical methods can now be employed and it has been possible to accurately predict many properties of bioactive molecules. Regardless, a model is worth nothing if it cannot be validated. Since the roots of computational chemistry etch back more than 40 years, there is virtually an infinite amount of different equations and principles used as well as

hundreds of compounds. One must prove that the given set trying to do the predicting is more accurate, less biased or arbitrary. Two methods have been proposed for the validation of the estimates made by computational models used for analysis of bioactive compounds. Here, these measures are presented along with the rationale behind them. Heightened interest in the study of proteomics has had profound effects on drug discovery and development. Combined with the understanding of individual DNA and how it influences such factors as cancer and obesity, it is now very possible to custom design drugs for each individual person. As a result, the race is now on in the pharmaceutical world to create the most powerful drugs tailored to an individual persons needs. Leaders in the field will undoubtedly possess a model that are able to predict the outcome of compounds before they are ever synthesized at a rate of millions of compounds a day.

14.1. Experimental Correlation

Tests typically focus on the structure activity relationship. The top materials research group was therefore interested in understanding the potential role the different trajectories of the virions play in attenuation. Theorists have suggested that a lack of collapsing the lattice causes the nontrivial attenuation of the mechanical response. The lattice imperfection associated with the improvement of the auxeticity takes different forms, with collapsing of the lattice believed to be the most robust way of preventing phase boundary movement. Simulations have given a consistency check. In the simulation, as the amplitude of the vibrational velocity was increased, the noncollapsing lattice began yielding showing that some of the soft response at low amplitude levels was phase boundary-related.

It was found in both experiments and simulations that the same abrupt change in the collapse was associated with an abrupt change in the decrease of transmission that occurs at approximately the same ndf. It has been suggested that the suppression of the collapsing at this density of infection is related to the robustness of the phase boundary to splitting and this seems to be confirmed with the suppression of the mechanical attenuation, also found to be optimal exactly at the same ndf. This study has raised the possibility of wider efforts to improve auxetic properties, in addition to the common ones typically focussed on property setup [40].

14.2. Benchmarking Techniques

The field of computational chemistry, particularly as applied to drug design, has rapidly come to its own in the last decade and a half. It has been fostered by an increasing understanding of the relationship between molecular structure and reactivity and by the development of the necessary computers and algorithms. It has become important, particularly as applied to the design of pharmaceuticals. The relative inaccessibility of proteins and nucleic acids to high-resolution structure determination, coupled with the emerging understanding of the relationships between macromolecular structure and function, have produced a number of successful computational strategies for such biomolecules. The pharmacophore modeling field centers mostly on tools for exploiting protein structures or sets of ligands known to bind to the particular target [41]. The tasks fall into the categories of binding-mode prediction, virtual screening, prediction of activity, and optimization of leads concerning patents. All of these approaches rely on an approximate description of the underlying energetics and kinetic. The rapid growth of the field has been accompanied by a similarly rapid proliferation of methods. Unfortunately, as long as the field has existed, a serious weakness within the field has been a lack of standards, both with respect to quantitative evaluation of methods and with respect to the preparation and distribution of data sets on which methods should be tested.

Concerns over the problem-led macrostructure increasingly informed efforts to automatically assemble training instances, with a diversity of polymers and blend compositions for the training set, as well as a range of goals across the property spectrum (ideally at least 30 goals; duly defined) [42]. To elaborate, the raw monomer smiles were parsed, and the training instance constructions proceeded in several stages. Embedding vectors were first generated for each

monomer. Motifs of up to three monomers were then assembled contingent on similarities in embedding space using unsupervised clustering, with metric used to quantify the similarity of two motifs. Predictors were then trained to evaluate each motif with respect to the goals, yielding motif desirabilities. To increase the diversity of polymers, sorted the motifs according to the mean desirability for a wide diversity of properties and then iteratively selected one of the motifs to place on the polymer chain. This procedure proceeds until the polymer length is reached. The construction of the blend was accomplished analogously by assembling monomer-commented embeddings for the monomers that are used to train nearest neighbor classifiers. Concatenating these properties also allowed the properties of a blend to be a feature in nearest neighbor selection.

15. Conclusion

Current developments in computational chemistry enabling rationalizing and accelerating personalized medicine and drug discovery are reviewed. A particular focus is on chemoinformatics developments, such as modeling compound - target interactions and the prediction of side effects of drugs, novel design strategies, as well as QSAR analysis of pharmacogenomic data of drug metabolism. Additionally, caveats in interpreting experimentally obtained results are outlined and the far-reaching impact on patient well-being and the healthcare system, beyond the research and drug development communities, is pointed out. In the case of cancer, possibility and obstacles of generalizations are discussed. These observations could stimulate further progress in computational methodology and its application to cancer and other complex diseases as well as a broader, substantial discussion on the associated socio-economical implications.

References:

1. V. V. Popov, E. V. Kudryavtseva, N. Kumar Katiyar, et al., "Industry 4.0 and digitalisation in healthcare," *Materials*, vol. 2022. mdpi.com
2. S. Paul, M. Riffat, A. Yasir, and M. N. Mahim, "Industry 4.0 applications for medical/healthcare services," *Journal of Sensor and Actuator Networks*, vol. 10, no. 2, 2021. mdpi.com
3. M. Javaid, A. Haleem, and R. P. Singh, "ChatGPT for healthcare services: An emerging stage for an innovative perspective," BenchCouncil Transactions on …, 2023. sciencedirect.com
4. V. T. Sabe, T. Ntombela, L. A. Jhamba, and others, "Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review," *Journal of Medicinal Chemistry*, vol. 2021, Elsevier. [HTML]
5. A. V. Sadybekov and V. Katritch, "Computational approaches streamlining drug discovery," Nature, 2023. nature.com
6. N. A. Murugan, A. Podobas, D. Gadioli, and E. Vitali, "A review on parallel virtual screening softwares for high-performance computers," *Pharmaceuticals*, vol. 15, no. 5, 2022. mdpi.com
7. J. Bajorath, "Computer-aided drug discovery," 2015. ncbi.nlm.nih.gov
8. L. G. Ferreira, R. N. dos Santos, G. Oliva, and A. D. Andricopulo, "Molecular Docking and Structure-Based Drug Design Strategies," 2015. ncbi.nlm.nih.gov
9. S. M. Kohlbacher, T. Langer, and T. Seidel, "QPHAR: quantitative pharmacophore activity relationship: method and validation," 2021. ncbi.nlm.nih.gov
10. D. W. Borhani and D. E. Shaw, "The future of molecular dynamics simulations in drug discovery," 2012. ncbi.nlm.nih.gov

11. M. Ahmed, A. M. Maldonado, and J. D. Durrant, "From byte to bench to bedside: molecular dynamics simulations and drug discovery," 2023. ncbi.nlm.nih.gov
12. N. Schapin, M. Majewski, A. Varela, C. Arroniz et al., "Machine Learning Small Molecule Properties in Drug Discovery," 2023. [PDF]
13. S. Shamsian, B. Sokouti, and S. Dastmalchi, "Benchmarking different docking protocols for predicting the binding poses of ligands complexed with cyclooxygenase enzymes and screening chemical libraries," BioImpacts: BI, 2023. nih.gov
14. Y. Zhou, Y. Jiang, and S. J. Chen, "RNA–ligand molecular docking: Advances and challenges," Wiley Interdisciplinary Reviews, vol. 2022. nih.gov
15. C. F. Lipinski, V. G. Maltarollo, P. R. Oliveira, A. B. F. da Silva et al., "Advances and Perspectives in Applying Deep Learning for Drug Design and Discovery," 2019. ncbi.nlm.nih.gov
16. A. M. Clark, K. Dole, A. Coulon-Spektor, A. McNutt et al., "Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets," 2015. ncbi.nlm.nih.gov
17. C. Bjerre Collin, T. Gebhardt, M. Golebiewski, T. Karaderi et al., "Computational Models for Clinical Applications in Personalized Medicine—Guidelines and Recommendations for Data Integration and Model Validation," 2022. ncbi.nlm.nih.gov
18. P. Moingeon, M. Kuenemann, and M. Guedj, "Artificial intelligence-enhanced drug design and development: Toward a computational precision medicine," Drug discovery today, 2022. science-inter.com
19. R. Han, H. Yoon, G. Kim, H. Lee et al., "Revolutionizing medicinal chemistry: the application of artificial intelligence (AI) in early drug discovery," Pharmaceuticals, 2023. mdpi.com
20. C. Mottini, F. Napolitano, Z. Li, X. Gao, "Computer-aided drug repurposing for cancer therapy: approaches and opportunities to challenge anticancer targets," Seminars in Cancer Biology, vol. 2021, Elsevier. sciencedirect.com
21. P. Barbiero and P. Lió, "The Computational Patient has Diabetes and a COVID," 2020. [PDF]
22. M. Vaduganathan, G. A. Mensah, J. V. Turco, et al., "The global burden of cardiovascular diseases and risk: a compass for future health," *Journal of the American College of Cardiology*, vol. 2022. jacc.org
23. A. Author1, B. Author2, and C. Author3, "Global effect of modifiable risk factors on cardiovascular disease and mortality," New England Journal of Medicine, vol. XX, no. YY, pp. ZZ-ZZ, 2023. nejm.org
24. D. Zhao, "Epidemiological features of cardiovascular disease in Asia," JACC: Asia, 2021. jacc.org
25. T. K. Dey and Y. Wang, "Computational topology for data analysis," 2022. [HTML]
26. E. N. Muratov, R. Amaro, C. H. Andrade, N. Brown, et al., "A critical overview of computational approaches employed for COVID-19 drug discovery," Chemical Society Reviews, vol. 50, no. 20, pp. 11245-11268, 2021. rsc.org
27. J. M. Hofman, D. J. Watts, S. Athey, F. Garip, T. L. Griffiths, et al., "Integrating explanation and prediction in computational social science," Nature, 2021. nsf.gov
28. A. Fant, "The Effect of Data Curation on the Accuracy of Quantitative Structure-Activity Relationship Models," 2015. [PDF]

29. ZN Ling, YF Jiang, JN Ru, JH Lu, B Ding, "Amino acid metabolism in health and disease," Signal Transduction and Targeted Therapy, vol. 8, no. 1, 2023. nature.com
30. C. Nie, A. K. Sahoo, R. R. Netz, A. Herrmann, "Charge matters: Mutations in omicron variant favor binding to cells," Wiley Online Library, 2022. wiley.com
31. H. Akkiz, "Implications of the novel mutations in the SARS-CoV-2 genome for transmission, disease severity, and the vaccine development," Frontiers in medicine, 2021. frontiersin.org
32. L. Xie, X. Ge, H. Tan, L. Xie et al., "Towards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine," 2014. ncbi.nlm.nih.gov
33. M. Bernetti, M. Bertazzo, and M. Masetti, "Data-Driven Molecular Dynamics: A Multifaceted Challenge," 2020. ncbi.nlm.nih.gov
34. S. K. Niazi and Z. Mariam, "Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis," 2023. ncbi.nlm.nih.gov
35. Q. Michaudel, Y. Ishihara, and P. S. Baran, "Academia–Industry Symbiosis in Organic Chemistry," 2015. ncbi.nlm.nih.gov
36. C. Choudhury, N. Arul Murugan, and U. Deva Priyakumar, "Structure-based drug repurposing: Traditional and advanced AI/ML-aided methods," 2022. ncbi.nlm.nih.gov
37. A. Al Saadi, D. Alfe, Y. Babuji, A. Bhati et al., "IMPECCABLE: Integrated Modeling PipelinE for COVID Cure by Assessing Better LEads," 2020. [PDF]
38. S. Eid, A. Zalewski, M. Smieško, B. Ernst et al., "A Molecular-Modeling Toolbox Aimed at Bridging the Gap between Medicinal Chemistry and Computational Sciences," 2013. ncbi.nlm.nih.gov
39. R. Gupta, D. Srivastava, M. Sahu, S. Tiwari et al., "Artificial intelligence to deep learning: machine intelligence approach for drug discovery," 2021. ncbi.nlm.nih.gov
40. J. Duda and S. Podlewska, "Low cost prediction of probability distributions of molecular properties for early virtual screening," 2022. [PDF]
41. A. N. Jain and A. Nicholls, "Recommendations for evaluation of computational methods," 2008. ncbi.nlm.nih.gov
42. A. K. Nigam, R. Pollice, G. Tom, K. Jorner et al., "Tartarus: A Benchmarking Platform for Realistic And Practical Inverse Molecular Design," 2022. [PDF]